METTL3 and colorectal carcinoma: Furthermore, a scientific study revealed that inhibiting M6A modification through the consumption of the methyltransferase enzymes METTL3/14 can potentiate the response of CRC subtypes to PD-1 immunotherapy, augmenting the efficacy of immune checkpoint blockade in treating CRC.